ESMO gratefully acknowledges the valuable contribution of the following organisations in the ESMO Sarcoma & GIST 2014 Conference as of 9 January 2014
At Novartis Oncology, we are passionate about the discovery and development of innovative medicines. We seek to provide a broad range of new therapies as well as practical solutions to advance the care of patients. With nearly 7,000 employees operating in 55 countries, Novartis Oncology has a truly global reach. We have the advantage of extraordinarily talented and globally diverse employees who, through shared goals and different perspectives, are dedicated to transforming the lives of patients living with cancer around the world. We have developed five new practice-changing medicines in the past decade, addressing unmet medical needs in patients worldwide. Our broad pipeline includes 27 new molecular entities in development, targeting key molecular pathways in cancer biology.
Our clinical development program consists of more than 20 biologics and small molecules with more than 100 ongoing clinical trials, including trials in lung, breast, renal cell, and hematologic malignancies. Our diverse portfolio includes a number of approved therapies in a range of cancers, including renal cell carcinoma, pancreatic neuroendocrine tumors, gastrointestinal stromal tumors as well as breast, colon, and rectal cancer.
PharmaMar is a Spanish biopharmaceutical company member of the Zeltia Group, committed to advancing the treatment of cancer through the discovery, development and commercialization of new marine-derived medicines. Its first product on the market, Yondelis, is the first marine-based anti-tumor drug developed by a Spanish company approved by the EMA. It is currently on the market for the treatment of advanced soft tissue sarcoma (STS) and relapsed ovarian cancer (ROC). PharmaMar also has a strong portfolio of marine origin compounds under preclinical and clinical development and a major R&D programme.
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Bayer HealthCare Pharmaceuticals
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer’s oncology franchise now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.